INTRODUCTION: Microbial translocation has been implicated as a contributing factor to the heightened immune activation observed during HIV-1 disease progression. When examined in a longitudinal study of HIV-1 seroconverters in Rakai, Uganda, microbial translocation was not associated with HIV-1 disease progression. However, the role of general immune activation in HIV disease progression in this population was not fully examined. METHODS: Longitudinal serum samples of HIV-1 seroconverters in three HIV-1 disease progression groups [long-term nonprogressors (LTNP), standard progressors (SP), and rapid progressors (RP)] from Rakai, Uganda, were tested for levels of C-reactive protein (CRP), a marker for immune activation. RESULTS: CRP levels significantly increased in the SP group (P < 0.0001) but not in the RP group or the LTNP group. CRP levels during the first year post-HIV seroconversion in the RP group were significantly higher than those observed in the LTNP group (P < 0.05). For the entire population, CRP levels negatively correlated with lipopolysaccharide levels (P < 0.05) and were not associated with endotoxin antibody levels. CONCLUSIONS: This study suggests that in this population, increased immune activation is significantly associated with HIV-1 disease progression but not microbial translocation.
INTRODUCTION: Microbial translocation has been implicated as a contributing factor to the heightened immune activation observed during HIV-1 disease progression. When examined in a longitudinal study of HIV-1 seroconverters in Rakai, Uganda, microbial translocation was not associated with HIV-1 disease progression. However, the role of general immune activation in HIV disease progression in this population was not fully examined. METHODS: Longitudinal serum samples of HIV-1 seroconverters in three HIV-1 disease progression groups [long-term nonprogressors (LTNP), standard progressors (SP), and rapid progressors (RP)] from Rakai, Uganda, were tested for levels of C-reactive protein (CRP), a marker for immune activation. RESULTS:CRP levels significantly increased in the SP group (P < 0.0001) but not in the RP group or the LTNP group. CRP levels during the first year post-HIV seroconversion in the RP group were significantly higher than those observed in the LTNP group (P < 0.05). For the entire population, CRP levels negatively correlated with lipopolysaccharide levels (P < 0.05) and were not associated with endotoxin antibody levels. CONCLUSIONS: This study suggests that in this population, increased immune activation is significantly associated with HIV-1 disease progression but not microbial translocation.
Authors: Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange Journal: Arch Intern Med Date: 2006-01-09
Authors: Andrew D Redd; Djeneba Dabitao; Jay H Bream; Blake Charvat; Oliver Laeyendecker; Noah Kiwanuka; Tom Lutalo; Godfrey Kigozi; Aaron A R Tobian; Jordyn Gamiel; Jessica D Neal; Amy E Oliver; Joseph B Margolick; Nelson Sewankambo; Steven J Reynolds; Maria J Wawer; David Serwadda; Ronald H Gray; Thomas C Quinn Journal: Proc Natl Acad Sci U S A Date: 2009-04-08 Impact factor: 11.205
Authors: Paul K Drain; Roland Kupka; Gernard I Msamanga; Willy Urassa; Ferdinand Mugusi; Wafaie W Fawzi Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Thorsten Demberg; Amelia C Ettinger; Stanley Aladi; Katherine McKinnon; Thea Kuddo; David Venzon; L Jean Patterson; Terry M Phillips; Marjorie Robert-Guroff Journal: Vaccine Date: 2011-06-25 Impact factor: 3.641
Authors: Andrew D Redd; Sarah K Wendel; Mary K Grabowski; Ponsiano Ocama; Valerian Kiggundu; Francis Bbosa; Iga Boaz; Ashwin Balagopal; Steven J Reynolds; Ronald H Gray; David Serwadda; Gregory D Kirk; Thomas C Quinn; Lara Stabinski Journal: AIDS Res Hum Retroviruses Date: 2013-05-08 Impact factor: 2.205
Authors: Vidya Mave; Kristine M Erlandson; Nikhil Gupte; Ashwin Balagopal; David M Asmuth; Thomas B Campbell; Laura Smeaton; Nagalingeswaran Kumarasamy; James Hakim; Breno Santos; Cynthia Riviere; Mina C Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Srikanth Tripathy; Noluthando Mwelase; Sima Berendes; Bruno B Andrade; David L Thomas; Robert C Bollinger; Amita Gupta Journal: J Infect Dis Date: 2016-03-08 Impact factor: 5.226
Authors: Lelia H Chaisson; Fred C Semitala; Lucy Asege; Sandra Mwebe; Jane Katende; Martha Nakaye; Alfred O Andama; Carina Marquez; Elly Atuhumuza; Moses Kamya; Adithya Cattamanchi; Christina Yoon Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Kaku A So-Armah; Joyce Chang; Charles Alcorn; Vincent Lo Re; Jason V Baker; Russell Tracy; Adeel A Butt; Brian K Agan; David Rimland; Cynthia L Gibert; Matthew B Goetz; Krisann K Oursler; Maria C Rodriguez-Barradas; Lewis H Kuller; Sheldon T Brown; James H Stein; Melissa Skanderson; Amy C Justice; Matthew S Freiberg Journal: Curr HIV Res Date: 2014 Impact factor: 1.581